The annual meeting of the American College of Rheumatology was held virtually this year from Nov. 3 to 9 and attracted participants from around the world, including rheumatology specialists, physicians, scientists, and other health professionals. The conference featured presentations focusing on the latest advances in the diagnosis and treatment of arthritis as well as other rheumatic and musculoskeletal diseases.
In one study, Yukiko Kimura, M.D., of the Hackensack University Medical Center in New Jersey, and colleagues found that children with polyarticular juvenile idiopathic arthritis (JIA) initially treated aggressively with a combination of biologic agents and conventional disease-modifying antirheumatic drugs (DMARDs) achieve clinically inactive disease more commonly when compared with other treatment approaches.
The authors used an observational prospective cohort design (not randomized) to determine the best time to start biologics in children and adolescents with polyarticular forms of JIA. Patients/families and providers chose between three treatment approaches: step up (DMARD only, adding a biologic if there is not enough improvement); early combination (DMARD and biologic together from the beginning); and biologic first (biologic treatment only). Patients’ clinical data from standard-of-care visits were entered into the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry every three months for one year, then twice a year until 24 months. The researchers found that after 24 months, children who were in all three groups improved over time, but the best outcomes in achieving clinically inactive disease were seen in the group that started the early combination (DMARD and a biologic from the beginning).
“Looking at these longer-term results may be more meaningful and important, because a more sustained and prolonged response likely means even better outcomes for patients who do respond, and less risk of joint damage and disability as they get older and become adults,” Kimura said. “This study is a demonstration that an observational comparative effectiveness study design of standardized treatments can successfully answer many important questions in rare diseases, for which randomized controlled trials are often not feasible and may not be applicable in real-world situations.”
Several authors disclosed financial ties to pharmaceutical companies.
In another prospective observational study conducted using the CARRA Registry, Tim Beukelman, M.D., of the University of Alabama at Birmingham, and colleagues found that most patients with systemic JIA receive biologic therapies early in the disease course, which is associated with positive patient outcomes.
The authors enrolled 73 patients, including 63 patients who started treatment with a biologic (interleukin-1 or interleukin-6 inhibitor) and 10 patients who started treatment with glucocorticoids alone or in combination with methotrexate. During a nine-month period, the researchers found that 57 percent of the patients reached clinical inactive disease without current glucocorticoid use, and 75 percent had disease activity scores of 2.5 or lower.
“Physicians and patients and their families should be comforted to know that initial treatment with biologics has become a standard treatment approach for systemic JIA and results in excellent short-term outcomes for the majority of patients,” Beukelman said.
Several authors disclosed financial ties to pharmaceutical companies.
Alfred Kim, M.D., Ph.D., of the Washington University School of Medicine in St. Louis, and colleagues found that patients with chronic inflammatory diseases (CIDs) who are being prescribed immunosuppressive therapies may mount a reduced antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination compared with their healthy counterparts.
The authors collected blood samples from 197 patients with CIDs and 53 healthy controls both before their first SARS-CoV-2 vaccination dose and one to two weeks after their second dose. The researchers found that most patients with CIDs do mount antibody responses following SARS-CoV-2 vaccination, but at the population level, responses were reduced by 3.4-fold. The greatest risk for antibody response reduction was among those taking B-cell depleting agents and glucocorticoids. Targeted therapies for CIDs had modest effects on antibody responses.
“This highlights that we must continue to not assume that all people, particularly the immunosuppressed, will generate protective responses against COVID-19,” Kim said. “We must counsel these patients that they need to continue preventative measures (masking, distancing).”
Several authors disclosed financial ties to pharmaceutical companies.
ACR: Risk Factors ID’d for Hydroxychloroquine-Related Retinopathy
TUESDAY, Nov. 16, 2021 (HealthDay News) — For patients prescribed hydroxychloroquine, cumulative dose, duration of use, chronic kidney disease, and Asian race are independent risk factors for incident HCQ retinopathy, according to a study presented at the annual meeting of the American College of Rheumatology, held virtually from Nov. 3 to 9.
ACR: Lupus Patients Can Have Low Immune Response to COVID-19 Vaccines
MONDAY, Nov. 15, 2021 (HealthDay News) — Nearly one-third of systemic lupus erythematosus patients have a low response to the COVID-19 vaccine, according to a study presented at the annual meeting of the American College of Rheumatology, held virtually from Nov. 3 to 9.
ACR: Total Hip Arthroplasty Up for Those Under Age 21
MONDAY, Nov. 15, 2021 (HealthDay News) — From 2000 to 2016, there was an increase in total hip arthroplasty among patients younger than 21 years of age in the United States, according to a study published in the December issue of the Journal of Arthroplasty to coincide with the annual meeting of the American College of Rheumatology, held virtually from Nov. 3 to 9.
ACR: Certain Serious Infections Down for Psoriatic Arthritis Patients
WEDNESDAY, Nov. 10, 2021 (HealthDay News) — There has been a decrease in hospital discharges for sepsis, skin and soft tissue infections, and urinary tract infections among patients with psoriatic arthritis during the past several years, according to a study presented at the annual meeting of the American College of Rheumatology, held virtually from Nov. 3 to 9.
ACR: COVID-19 Vaccine Not Tied to Severe Rheumatic Disease Flares
WEDNESDAY, Nov. 10, 2021 (HealthDay News) — Receipt of an mRNA COVID-19 vaccine is not associated with severe disease flares in patients with rheumatic diseases, according to a study presented at the annual meeting of the American College of Rheumatology, held virtually from Nov. 3 to 9.
ACR: Cycling JAK Inhibitors Feasible for Difficult-to-Treat RA
TUESDAY, Nov. 9, 2021 (HealthDay News) — People with difficult-to-treat rheumatoid arthritis that does not respond to one Janus kinase inhibitor may achieve a similar response by either cycling to other JAKi medications or switching to a biologic drug, according to a study presented at the annual meeting of the American College of Rheumatology, held virtually from Nov. 3 to 9.
Copyright © 2021 HealthDay. All rights reserved.
